English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine BioTech
康哲药业建议于新加坡交易所第二上市
Jun 25, 2025 17:24 HKT
新冠疫情多地爆發 楷和醫療求診數量增
Jun 24, 2025 08:04 HKT
ZeptoMetrix Launches H5N1 Control With Phage-Like Particle (PLP) Technology
Jun 23, 2025 21:00 HKT
華領醫藥在2025ADA科學年會公佈多格列艾汀與DPP-4抑制劑聯用在恢復血糖穩態的同時有望降低血脂
Jun 23, 2025 15:09 HKT
华领医药在2025ADA科学年会公布多格列艾汀与DPP-4抑制剂联用在恢复血糖稳态的同时有望降低血脂
Jun 23, 2025 11:11 HKT
康希諾重磅推出優佩欣疫苗 為兒童健康保駕護航的創新之選
Jun 21, 2025 12:09 HKT
康希诺重磅推出优佩欣疫苗 为儿童健康保驾护航的创新之选
Jun 20, 2025 17:58 HKT
雲頂新耀加速全球佈局 耐賦康(R)與EVER001雙引擎釋放創新藥價值潛力
Jun 20, 2025 14:49 HKT
云顶新耀加速全球布局 耐赋康(R)与EVER001双引擎释放创新药价值潜力
Jun 20, 2025 14:42 HKT
NEFECON(R) and EVER001 Drive Synergistic Progress as Everest Medicines Advances
Jun 12, 2025 16:38 HKT
耐賦康(R)與EVER001協同發力 雲頂新耀推動腎病治療進入精準管理新階段
Jun 12, 2025 16:31 HKT
耐赋康(R)与EVER001协同发力 云顶新耀推动肾病治疗进入精准管理新阶段
Jun 12, 2025 16:26 HKT
Everest Medicines Presents Positive Results from Phase 1b/2a Clinical Trial of EVER001 for Primary Membranous Nephropathy at ERA 2025
Jun 09, 2025 12:52 HKT
雲頂新耀EVER001亮相ERA 2025 探索原發性膜性腎病治療新路徑
Jun 09, 2025 12:47 HKT
云顶新耀EVER001亮相ERA 2025 探索原发性膜性肾病治疗新路径
Jun 09, 2025 12:35 HKT
First patient dosed in YK012 trial-the world's first TCE therapy for primary membranous nephropathy
May 29, 2025 15:49 HKT
Asia Summit on Global Health and Hong Kong International Medical and Healthcare Fair Wrap Up Successfully
May 28, 2025 19:57 HKT
「國際醫療健康周」今日揭開序幕
May 27, 2025 12:34 HKT
「国际医疗健康周」今日揭开序幕
May 27, 2025 12:04 HKT
International Healthcare Week kicks off today
May 26, 2025 18:27 HKT
<< Previous  Next >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: